CO5700743A2 - Formas polimorficas de un agonista de gaba a - Google Patents
Formas polimorficas de un agonista de gaba aInfo
- Publication number
- CO5700743A2 CO5700743A2 CO06073254A CO06073254A CO5700743A2 CO 5700743 A2 CO5700743 A2 CO 5700743A2 CO 06073254 A CO06073254 A CO 06073254A CO 06073254 A CO06073254 A CO 06073254A CO 5700743 A2 CO5700743 A2 CO 5700743A2
- Authority
- CO
- Colombia
- Prior art keywords
- peak
- powder
- values
- ray diffraction
- cuka radiation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
1.- El compuesto monohidrato de gaboxadol en una forma cristalina.2.- El compuesto de acuerdo con la reivindicación 1 en una forma cristalina seleccionada de: (a) forma I la cual se caracteriza por un espectro de difracción de rayos X en polvo en valores de 2? usando radiación CuKa que tiene un pico a 11,5°; y (b) forma II la cual se caracteriza por un espectro de difracción de rayos X en polvo en valores de 2? usando radiación CuKa que tiene un pico a 25,2°.3.- El compuesto de acuerdo con la reivindicación 2 el cual es monohidrato de gaboxadol cristalino de forma II el cual se caracteriza por un espectro de difracción de rayos X en polvo en valores de 2? usando radiación CuKa que tiene un pico a 25,2°.4.- El compuesto de acuerdo con la reivindicación 3 el cual se caracteriza adicionalmente mediante cambios químicos en RMN 13C en el estado sólido de 17,5, 40,3, 102,2, 158,5 y 172,5 ppm con referencia a un valor de 176,03 ppm para el pico carbonilo de glicina.5.- El compuesto anhidrato de gaboxadol en una forma cristalina seleccionada de: (a) forma I la cual se caracteriza por un espectro de difracción de rayos X en polvo en valores de 2? usando radiación CuKa que tiene un pico a 12,8°; y (b) forma II la cual se caracteriza por un espectro de difracción de rayos X en polvo en valores de 2? usando radiación CuKa que tiene un pico a uno o más de 16,0°, 24,7° y 28,4°.6.- El compuesto de acuerdo con reivindicación 5 el cual es anhidrato de gaboxadol cristalino de forma II el cual se caracteriza mediante un espectro de difracción de rayos X en polvo en valores de 2? usando radiación CuKa que tiene un pico a uno o más de 16,0°, 24,7° y 28,4° en la ausencia de un pico a 12,8°.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0402118.4A GB0402118D0 (en) | 2004-01-30 | 2004-01-30 | Polymorphic forms of a GABAA agonist |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5700743A2 true CO5700743A2 (es) | 2006-11-30 |
Family
ID=31971783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO06073254A CO5700743A2 (es) | 2004-01-30 | 2006-07-26 | Formas polimorficas de un agonista de gaba a |
Country Status (35)
Country | Link |
---|---|
US (2) | US7262300B2 (es) |
EP (2) | EP1713813B1 (es) |
JP (1) | JP4917440B2 (es) |
KR (1) | KR101210361B1 (es) |
CN (1) | CN1914212B (es) |
AR (1) | AR047511A1 (es) |
AT (1) | ATE414088T1 (es) |
AU (1) | AU2005209473B2 (es) |
BR (1) | BRPI0506858A (es) |
CA (1) | CA2554536C (es) |
CO (1) | CO5700743A2 (es) |
CY (1) | CY1108647T1 (es) |
DE (1) | DE602005010975D1 (es) |
DK (1) | DK1713813T3 (es) |
DO (1) | DOP2005000013A (es) |
EA (1) | EA009413B1 (es) |
EC (1) | ECSP066735A (es) |
ES (1) | ES2314613T3 (es) |
GB (2) | GB0402118D0 (es) |
HK (1) | HK1096547A1 (es) |
HR (1) | HRP20080614T3 (es) |
IL (1) | IL176863A0 (es) |
MA (1) | MA28364A1 (es) |
MX (1) | MXPA06008595A (es) |
MY (1) | MY139525A (es) |
NO (1) | NO20063843L (es) |
NZ (1) | NZ548191A (es) |
PE (1) | PE20050769A1 (es) |
PL (1) | PL1713813T3 (es) |
PT (1) | PT1713813E (es) |
SI (1) | SI1713813T1 (es) |
TW (1) | TWI345972B (es) |
UA (1) | UA87487C2 (es) |
WO (1) | WO2005073237A2 (es) |
ZA (1) | ZA200605307B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0402118D0 (en) | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
US20060063802A1 (en) | 2004-03-29 | 2006-03-23 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
US9072662B2 (en) | 2004-03-29 | 2015-07-07 | Auris Medical Ag | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
US8268866B2 (en) | 2004-03-29 | 2012-09-18 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
DE102005004343A1 (de) * | 2005-01-25 | 2006-08-10 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Behandlung von Phantomphänomenen |
US8022084B2 (en) | 2005-01-28 | 2011-09-20 | H. Lundbeck A/S | Polymorphic forms of a GABAA agonist |
SI1928405T1 (sl) | 2005-09-28 | 2014-12-31 | Auris Medical Ag | Farmacevtski sestavki za zdravljenje motenj notranjega ušesa |
CN102093387B (zh) * | 2009-12-10 | 2012-07-25 | 天津泰普医药知识产权流转储备中心有限公司 | 4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-醇一水合物的晶型化合物 |
US20150044200A1 (en) | 2011-12-12 | 2015-02-12 | Otolanum Ag | Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system |
KR20180031721A (ko) * | 2015-07-17 | 2018-03-28 | 오비드 테라퓨틱스 인크. | 가복사돌로 발달장애들을 치료하는 방법들 |
KR102518846B1 (ko) | 2016-08-11 | 2023-04-05 | 오비드 테라퓨틱스 인크. | 간질 장애의 치료를 위한 방법 및 조성물 |
EP3528807A4 (en) * | 2016-11-22 | 2020-06-17 | Ovid Therapeutics Inc | METHOD FOR TREATING DEVELOPMENT DISORDERS AND / OR FALLS WITH FLUPIRTIN |
US10071083B2 (en) * | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
WO2019028234A1 (en) | 2017-08-04 | 2019-02-07 | Ovid Therapeutics Inc. | USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS |
MX2021003302A (es) | 2018-09-20 | 2021-05-13 | Ovid Therapeutics Inc | Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez. |
EP3883566A4 (en) | 2018-11-21 | 2022-09-07 | Certego Therapeutics Inc. | GABOXADOL FOR SUICIDE RISK REDUCTION AND RAPID DEPRESSION RELIEF |
CA3123876A1 (en) | 2018-12-17 | 2020-06-25 | Ovid Therapeutics Inc. | Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder |
EP4051272A4 (en) | 2019-12-18 | 2023-01-04 | Ovid Therapeutics Inc. | GABOXADOL FOR THE THERAPEUTIC TREATMENT OF 1p36 DELETION SYNDROME |
CA3182508A1 (en) | 2020-05-20 | 2021-11-25 | Certego Therapeutics Inc. | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK270278A (da) | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Cycliske aminosyrer |
US4315934A (en) | 1979-09-24 | 1982-02-16 | Sandoz Ltd. | Organic compounds |
US4362731A (en) | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
US4352731A (en) * | 1980-11-03 | 1982-10-05 | Occidental Research Corporation | Apparatus for selective wetting of particles |
DE19525598C2 (de) | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | Schlafmittel |
UA52661C2 (uk) * | 1996-06-14 | 2003-01-15 | Ново Нордіск А/С | Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти |
CA2385749A1 (en) | 1999-09-28 | 2001-04-05 | H. Lundbeck A/S | Melt granulated composition and modified release dosage form prepared from said composition |
AR031473A1 (es) | 2000-11-20 | 2003-09-24 | Lundbeck & Co As H | Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide |
WO2002094255A1 (de) | 2001-05-18 | 2002-11-28 | Lonza Ag | Verfahren zur herstellung fester formulierungen von natrium-3-hydroxy-3-methylbutyrat |
AR033896A1 (es) | 2001-05-21 | 2004-01-07 | Lundbeck & Co As H | Preparaciones granuladas de gaboxadol. |
WO2004022550A1 (en) * | 2002-09-03 | 2004-03-18 | Naturon Limited | Compound for treatment of anxiety and methods of preparation and use thereof |
US20050234093A1 (en) * | 2003-06-25 | 2005-10-20 | H. Lundbeck A/S | Treatment of depression and other affective disorders |
ES2341004T3 (es) * | 2003-06-25 | 2010-06-14 | H. Lundbeck A/S | Gaboxadol para tratar la depresion y otros trastornos afectivos. |
AR045540A1 (es) | 2003-09-05 | 2005-11-02 | Lundbeck & Co As H | Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip) |
EP1663218A1 (en) | 2003-09-10 | 2006-06-07 | MERCK SHARP & DOHME LTD. | Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome |
TW200528098A (en) | 2003-12-18 | 2005-09-01 | Lundbeck & Co As H | Treatment of insomnia in human patients |
GB0402118D0 (en) | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
EA200700102A1 (ru) | 2004-06-29 | 2007-06-29 | Х.Лундбекк А/С | Лечение невропатической боли, фибромиалгии или ревматоидного артрита |
GB0417558D0 (en) | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Novel combination therapy |
US8022084B2 (en) * | 2005-01-28 | 2011-09-20 | H. Lundbeck A/S | Polymorphic forms of a GABAA agonist |
EP1863808A1 (en) | 2005-03-18 | 2007-12-12 | Transform Pharmaceuticals, Inc. | Gaboxadol forms, compositions thereof, and related methods |
EP1906953A4 (en) | 2005-04-29 | 2009-05-20 | Lundbeck & Co As H | FORMS OF ACID SALTS AND BASIC SALTS OF GABOXADOL |
-
2004
- 2004-01-30 GB GBGB0402118.4A patent/GB0402118D0/en not_active Ceased
-
2005
- 2005-01-20 AR ARP050100210A patent/AR047511A1/es not_active Application Discontinuation
- 2005-01-21 TW TW094101857A patent/TWI345972B/zh not_active IP Right Cessation
- 2005-01-24 MY MYPI20050253A patent/MY139525A/en unknown
- 2005-01-27 PE PE2005000102A patent/PE20050769A1/es not_active Application Discontinuation
- 2005-01-28 AT AT05702040T patent/ATE414088T1/de active
- 2005-01-28 DE DE602005010975T patent/DE602005010975D1/de active Active
- 2005-01-28 DO DO2005000013A patent/DOP2005000013A/es unknown
- 2005-01-28 JP JP2006550301A patent/JP4917440B2/ja active Active
- 2005-01-28 EA EA200601404A patent/EA009413B1/ru not_active IP Right Cessation
- 2005-01-28 CA CA2554536A patent/CA2554536C/en not_active Expired - Fee Related
- 2005-01-28 PT PT05702040T patent/PT1713813E/pt unknown
- 2005-01-28 CN CN2005800031615A patent/CN1914212B/zh active Active
- 2005-01-28 UA UAA200609410A patent/UA87487C2/ru unknown
- 2005-01-28 PL PL05702040T patent/PL1713813T3/pl unknown
- 2005-01-28 SI SI200530521T patent/SI1713813T1/sl unknown
- 2005-01-28 DK DK05702040T patent/DK1713813T3/da active
- 2005-01-28 NZ NZ548191A patent/NZ548191A/en not_active IP Right Cessation
- 2005-01-28 ES ES05702040T patent/ES2314613T3/es active Active
- 2005-01-28 US US11/045,768 patent/US7262300B2/en active Active
- 2005-01-28 WO PCT/GB2005/000288 patent/WO2005073237A2/en active Search and Examination
- 2005-01-28 EP EP05702040A patent/EP1713813B1/en active Active
- 2005-01-28 BR BRPI0506858-4A patent/BRPI0506858A/pt not_active IP Right Cessation
- 2005-01-28 GB GB0501847A patent/GB2410434A/en not_active Withdrawn
- 2005-01-28 AU AU2005209473A patent/AU2005209473B2/en not_active Ceased
- 2005-01-28 MX MXPA06008595A patent/MXPA06008595A/es active IP Right Grant
- 2005-01-28 EP EP08019457A patent/EP2042505A1/en not_active Withdrawn
-
2006
- 2006-06-27 ZA ZA200605307A patent/ZA200605307B/en unknown
- 2006-07-13 IL IL176863A patent/IL176863A0/en unknown
- 2006-07-26 CO CO06073254A patent/CO5700743A2/es not_active Application Discontinuation
- 2006-07-28 EC EC2006006735A patent/ECSP066735A/es unknown
- 2006-07-28 KR KR1020067015417A patent/KR101210361B1/ko not_active IP Right Cessation
- 2006-08-22 MA MA29278A patent/MA28364A1/fr unknown
- 2006-08-29 NO NO20063843A patent/NO20063843L/no not_active Application Discontinuation
-
2007
- 2007-02-23 HK HK07102068A patent/HK1096547A1/xx unknown
- 2007-07-13 US US11/827,570 patent/US8236958B2/en active Active
-
2008
- 2008-11-26 HR HR20080614T patent/HRP20080614T3/xx unknown
- 2008-12-10 CY CY20081101439T patent/CY1108647T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5700743A2 (es) | Formas polimorficas de un agonista de gaba a | |
AR108819A2 (es) | Formas polimórficas de un inhibidor macrocíclico de vhc | |
CR9244A (es) | AMINO-IMIDAZOLONAS PARA LA INHIBICION DE ß-SECRETASA | |
WO2007028135A3 (en) | Imidazopyridine compounds | |
AR111812A2 (es) | Compuestos y composiciones para el control de nematodos | |
EA200600407A1 (ru) | Полупроводниковые плёнки из четырёх и более компонентных сплавов элементов групп i-iii-vi | |
CO6321230A2 (es) | Compuesto espiro, una sal aceptable para uso farmaceutico y un solvato del mismo y composicion farmaceutica que lo contenga | |
GB0521508D0 (en) | Organic compounds | |
WO2006133147A3 (en) | Organic compounds | |
EA200601274A1 (ru) | Новая кристаллическая форма iii агомелатина, способ её получения и фармацевтические композиции, которые её содержат | |
EA200800321A1 (ru) | Ингибиторы гистондеацетилазы | |
CL2008002703A1 (es) | Compuestos derivados de 1,4-dihidro-2h-piridazin-3-ona; composicion herbicida que comprende a dichos compuestos; metodo de control de malezas; uso de dichos compuestos para el control de malezas; y compuestos intermediarios. | |
DE602005023333D1 (de) | Kinaseinhibitoren | |
TW200706636A (en) | Compounds for organic electronic devices | |
TW200702421A (en) | Compounds for organic electronic devices | |
WO2007078813A3 (en) | 2-AMINO-5-PIPERIDINYLIMIDAZOLONE COMPOUNDS AND USE THEREOF FOR β-SECRETASE MODULATION | |
UY28014A1 (es) | Compuestos quimicos | |
GEP20115251B (en) | Smac peptidomimetics useful as iap inhibitors | |
WO2007075964A3 (en) | Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery | |
WO2007076245A3 (en) | Novel hydrogen sulfate salt | |
GEP20125523B (en) | Metabolites of (thio) carbamoyl-cyclohexane derivatives | |
MXPA05008367A (es) | Derivados de pirazol. | |
CR8350A (es) | 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogenica cronica | |
HK1164114A1 (en) | Antidepressant containing heterocyclic compound having specific structure | |
CR10722A (es) | Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintetasa quinasa 3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |